Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$22.33 +1.6%	$20.68	$17.45 ▼ $70.07	$855.66M	0.19	913,206 shs	612,485 shs
NTLA Intellia Therapeutics	$9.60 +0.2%	$8.24	$5.90 ▼ $28.18	$994.39M	2.14	2.88 million shs	5.76 million shs
PRVA Privia Health Group	$21.81 -2.6%	$23.41	$16.37 ▼ $26.09	$2.66B	0.83	744,289 shs	909,223 shs
RYTM Rhythm Pharmaceuticals	$61.48 -0.8%	$62.30	$39.46 ▼ $69.89	$3.91B	2.3	556,592 shs	622,915 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	+1.78%	+1.48%	-0.31%	-8.02%	-57.49%
NTLA Intellia Therapeutics	+0.21%	+14.70%	+5.96%	+10.34%	-61.29%
PRVA Privia Health Group	-2.59%	-5.22%	-12.76%	-6.35%	+27.32%
RYTM Rhythm Pharmaceuticals	-0.79%	-5.18%	+0.38%	+13.37%	+48.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.3377 of 5 stars	3.1	2.0	4.3	2.9	1.7	1.9
NTLA Intellia Therapeutics	4.4339 of 5 stars	4.3	1.0	4.7	2.4	2.5	0.6
PRVA Privia Health Group	4.3357 of 5 stars	4.5	3.0	0.0	2.8	3.3	1.9
RYTM Rhythm Pharmaceuticals	4.1129 of 5 stars	3.5	3.0	4.3	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	43.67% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	264.06% Upside
PRVA Privia Health Group	3.00	Buy	$27.77	27.32% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	24.62% Upside

Current Analyst Ratings Breakdown

Latest AMN, PRVA, RYTM, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/28/2025	PRVA Privia Health Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $32.00
5/27/2025	PRVA Privia Health Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$23.00 ➝ $24.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/13/2025	AMN AMN Healthcare Services	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.50

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.98B	0.29	$13.70 per share	1.63	$18.56 per share	1.20
NTLA Intellia Therapeutics	$57.88M	17.18	N/A	N/A	$8.56 per share	1.12
PRVA Privia Health Group	$1.74B	1.53	$0.18 per share	120.87	$5.70 per share	3.83
RYTM Rhythm Pharmaceuticals	$130.13M	30.06	N/A	N/A	$0.35 per share	175.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	9.23	N/A	-5.80%	13.39%	4.17%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
PRVA Privia Health Group	$14.39M	$0.12	181.77	80.78	3.49	0.87%	2.32%	1.38%	8/14/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest AMN, PRVA, RYTM, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PRVA Privia Health Group	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.39	1.08	1.08
NTLA Intellia Therapeutics	N/A	4.90	4.90
PRVA Privia Health Group	N/A	1.88	1.88
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
NTLA Intellia Therapeutics	88.77%
PRVA Privia Health Group	94.48%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
NTLA Intellia Therapeutics	3.10%
PRVA Privia Health Group	10.70%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	2,968	38.28 million	37.93 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
PRVA Privia Health Group	1,140	121.92 million	108.88 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

AMN, PRVA, RYTM, and NTLA Headlines

Recent News About These Companies

22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A.

June 18 at 3:39 AM | marketbeat.com

SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18 at 3:39 AM | marketbeat.com

GAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18 at 3:13 AM | marketbeat.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 2,069 Shares of Stock

June 12, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Rating of "Buy" by Analysts

June 12, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Buy" from Analysts

June 12, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Buys 47,045 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wedge Capital Management L L P NC

June 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $478,459.55 in Stock

June 10, 2025 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Should You Buy?

June 9, 2025 | marketbeat.com

The Rhythm Foundation seeks contract extension to continue programming at Miami Beach Bandshell

June 7, 2025 | msn.com

Heartbeats That Matter: The Silent Risks of Heart Rhythm Disorders

June 7, 2025 | deccanchronicle.com

Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 7, 2025 | marketbeat.com

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

June 5, 2025 | msn.com

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

June 5, 2025 | benzinga.com

Hennion & Walsh Asset Management Inc. Has $4.75 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 4, 2025 | marketbeat.com

76,084 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Universal Beteiligungs und Servicegesellschaft mbH

June 2, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Holdings Cut by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 31, 2025 | marketbeat.com

Stifel Nicolaus Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $94.00

May 30, 2025 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 4.7% - Here's Why

May 30, 2025 | marketbeat.com

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism

May 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN, PRVA, RYTM, and NTLA Company Descriptions

AMN Healthcare Services NYSE:AMN

$22.33 +0.34 (+1.55%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$22.36 +0.02 (+0.11%)

As of 06/18/2025 04:20 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Intellia Therapeutics NASDAQ:NTLA

$9.60 +0.02 (+0.21%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.30 -0.31 (-3.18%)

As of 06/18/2025 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Privia Health Group NASDAQ:PRVA

$21.81 -0.58 (-2.59%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$23.26 +1.46 (+6.67%)

As of 06/18/2025 05:55 PM Eastern

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.48 -0.49 (-0.79%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$61.50 +0.02 (+0.03%)

As of 06/18/2025 05:47 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time